Interleukin 2 Receptor-directed Antibody Interactions

Name

Interleukin 2 Receptor-directed Antibody Interactions

Accession Number

DBCAT004303

Description

Not Available

Drugs

Drug	Drug Description
Daclizumab	A monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
Basiliximab	A monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.

Drugs & Drug Targets

Drug	Target	Type
Daclizumab	Interleukin-2 receptor subunit alpha	target
Daclizumab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
Daclizumab	Complement C1r subcomponent	target
Daclizumab	Complement C1q subcomponent subunit A	target
Daclizumab	Complement C1q subcomponent subunit B	target
Daclizumab	Complement C1q subcomponent subunit C	target
Daclizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
Daclizumab	High affinity immunoglobulin gamma Fc receptor I	target
Daclizumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
Daclizumab	Interleukin-2 receptor subunit beta	target
Daclizumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
Daclizumab	Low affinity immunoglobulin gamma Fc region receptor II-c	target
Basiliximab	Interleukin-2 receptor subunit alpha	target
Basiliximab	Interleukin-2 receptor subunit beta	target